Versiti Acquires Quantigen

Versiti Acquires Pearl Pathways

November 7, 2023

Healthcare Services

Versiti, a Milwaukee-based blood health organization, has acquired Pearl Pathways, an Indianapolis-area life science consulting firm that provides regulatory affairs, quality compliance, CRO services and an independent IRB. The acquisition expands Versiti's clinical trial and life-sciences service capabilities, enabling earlier and deeper support for product development across biopharmaceutical, medical device, and diagnostics clients.

Versiti Acquires Ethical and Independent Review Services (E&I)

July 12, 2022

Healthcare Services

Versiti, a national blood health organization headquartered in Milwaukee, has acquired Missouri-based Ethical and Independent Review Services (E&I), an AAHRPP-accredited independent IRB. The acquisition expands Versiti's clinical trial services and regulatory review capabilities across biopharmaceutical, medical device, and social/behavioral research markets.

Versiti Acquires Solvita Blood Center (formerly Community Blood Center)

November 4, 2024

Healthcare Services

Versiti Blood Center of Ohio has acquired Solvita Blood Center (formerly Community Blood Center) to expand Versiti's footprint and blood donation services in the Dayton, Ohio region. The transaction transfers Solvita's blood center operations to Versiti while Solvita retains its global tissue services.

Veristat Acquires SQN Clinical

February 25, 2021

Healthcare Services

Veristat acquired SQN Clinical to expand its biometrics capabilities and strengthen its European footprint. The acquisition adds more than 80 employees and integrates SQN Clinical's clinical data management, biostatistics and project management capabilities into Veristat's global CRO services.

Discovery Life Sciences Acquires QualTek Molecular Laboratories

May 5, 2019

Healthcare Services

Discovery Life Sciences (based in Huntsville, Alabama) has acquired QualTek Molecular Laboratories, a provider of CAP/CLIA-accredited and GLP-capable immunohistochemistry (IHC) laboratories in California and Pennsylvania. The acquisition expands Discovery's histopathology and IHC assay development capabilities and integrates QualTek's services with Discovery's biospecimen, sequencing, flow cytometry and multiomic annotation offerings to accelerate biomarker validation and drug/diagnostic development.

Agilent Technologies Acquires BIOVECTRA for $925M

July 22, 2024

Pharmaceuticals

Agilent Technologies has acquired BIOVECTRA, a Canada-based contract development and manufacturing organization (CDMO), for $925 million. The acquisition — a purchase from H.I.G. Capital — expands Agilent's CDMO capabilities across biologics, HPAPIs, pDNA/mRNA and LNP formulation, and integrates BIOVECTRA into Agilent's Diagnostics and Genomics Group.